BRAF and melanoma: While a manageable safety profile and a low discontinuation rate have been shown using encorafenib and binimetinib for advanced BRAF-mutated melanoma [8, 9], safety information for the triplet and doublet regimens of encorafenib plus cetuximab with and without binimetinib for BRAF V600E-mutated colorectal cancer has been limited in Japanese patients because only 3 and 6 patients were enrolled in Japan for evaluation of the triplet and doublet regimens, respectively, in the BEACON CRC study.